Literature DB >> 19428856

Invasive pneumococcal disease in the Netherlands: Syndromes, outcome and potential vaccine benefits.

Angelique G S C Jansen1, Gerwin D Rodenburg, Sabine C de Greeff, Eelko Hak, Reinier H Veenhoven, Lodewijk Spanjaard, Leo M Schouls, Elisabeth A M Sanders, Arie van der Ende.   

Abstract

With a retrospective study of invasive pneumococcal disease (IPD) surveillance data representative for approximately 25% of the Dutch population (1275 hospitalized cases) over the period June 2004-June 2006 prior to the implementation of the 7-valent pneumococcal conjugate vaccine (PCV7), the aim was to provide baseline data on IPD for the interpretation of changes after implementation of conjugate vaccines. The IPD incidence peaked in 3-5-mnth-olds (63 cases per 100,000 persons yearly) and increased in adulthood, particularly after the age of 60yrs, from 26 cases in 60-64-yr-olds to 97 cases per 100,000 in persons > or =90yrs. Beyond the age of 4yrs, 19% of IPD patients were immunocompromised, and this considerable percentage may have implications for vaccine efficacy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19428856     DOI: 10.1016/j.vaccine.2009.01.127

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  20 in total

Review 1.  Vaccination in the elderly: what can be recommended?

Authors:  Pierre-Olivier Lang; Richard Aspinall
Journal:  Drugs Aging       Date:  2014-08       Impact factor: 3.923

2.  Nasopharyngeal colonization elicits antibody responses to staphylococcal and pneumococcal proteins that are not associated with a reduced risk of subsequent carriage.

Authors:  Sabine M P J Prevaes; Willem J B van Wamel; Corné P de Vogel; Reinier H Veenhoven; Elske J M van Gils; Alex van Belkum; Elisabeth A M Sanders; Debby Bogaert
Journal:  Infect Immun       Date:  2012-03-26       Impact factor: 3.441

3.  A few years later. Update of the cost-effectiveness of infant pneumococcal vaccination in Dutch children.

Authors:  Pepijn Vemer; Maarten J Postma
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

4.  Validation of an immunodiagnostic assay for detection of 13 Streptococcus pneumoniae serotype-specific polysaccharides in human urine.

Authors:  Michael W Pride; Susanne M Huijts; Kangjian Wu; Victor Souza; Sherry Passador; Chunyan Tinder; Esther Song; Arik Elfassy; Lisa McNeil; Ronald Menton; Roger French; Janice Callahan; Chris Webber; William C Gruber; Marc J M Bonten; Kathrin U Jansen
Journal:  Clin Vaccine Immunol       Date:  2012-06-06

5.  Optimization and application of a multiplex bead-based assay to quantify serotype-specific IgG against Streptococcus pneumoniae polysaccharides: response to the booster vaccine after immunization with the pneumococcal 7-valent conjugate vaccine.

Authors:  Karin E M Elberse; Irina Tcherniaeva; Guy A M Berbers; Leo M Schouls
Journal:  Clin Vaccine Immunol       Date:  2010-02-03

Review 6.  Cost effectiveness of the new pneumococcal vaccines: a systematic review of European studies.

Authors:  Katelijne van de Vooren; Silvy Duranti; Alessandro Curto; Livio Garattini
Journal:  Pharmacoeconomics       Date:  2014-01       Impact factor: 4.981

Review 7.  The role of the local microbial ecosystem in respiratory health and disease.

Authors:  Wouter A A de Steenhuijsen Piters; Elisabeth A M Sanders; Debby Bogaert
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2015-08-19       Impact factor: 6.237

8.  Effects of pneumococcal conjugate vaccine 2 years after its introduction, the Netherlands.

Authors:  Gerwin D Rodenburg; Sabine C de Greeff; Angelique G C S Jansen; Hester E de Melker; Leo M Schouls; Eelko Hak; Lodewijk Spanjaard; Elisabeth A M Sanders; Arie van der Ende
Journal:  Emerg Infect Dis       Date:  2010-05       Impact factor: 6.883

Review 9.  Assessment of vaccine candidates for persons aged 50 and older: a review.

Authors:  Renske Eilers; Paul F M Krabbe; Ted G A van Essen; Anita Suijkerbuijk; Alies van Lier; Hester E de Melker
Journal:  BMC Geriatr       Date:  2013-04-15       Impact factor: 3.921

10.  Invasive pneumococcal disease and 7-valent pneumococcal conjugate vaccine, the Netherlands.

Authors:  Anna M M van Deursen; Suzan P van Mens; Elisabeth A M Sanders; Bart J M Vlaminckx; Hester E de Melker; Leo M Schouls; Sabine C de Greeff; Arie van der Ende
Journal:  Emerg Infect Dis       Date:  2012-11       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.